Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: Short- and long-term effects

Leukemia

Volumn 14, Issue 10, 2000, Pages 1736-1742

  Arnaout, M K ^a   Radomski, K M ^a   Srivastava, D K ^a   Tong, X ^a   Belt, J R ^a   Raimondi, S C ^a   Behm, F G ^a   Santana, V M ^a,b   Crom, W R ^a   Mirro Jr , J ^a,b   Ribeiro, R C ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

AML; Children; Cytarabine; Etoposide; Late effects; Pediatric

Indexed keywords

AMSACRINE; AZACITIDINE; COTRIMOXAZOLE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; HYDROCORTISONE; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CATARACT; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; ENDOCRINE DISEASE; FEMALE; HEARING LOSS; HEART FAILURE; HEPATITIS C; HUMAN; INTENSIVE CARE; LEARNING DISORDER; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; NEUTROPENIA; OBESITY; PEDIATRICS; PNEUMONIA; PRIORITY JOURNAL; SEIZURE; SPEECH DISORDER;

EID: 20244371944     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401906     Document Type: Article

References (33)

1. Acute leukemia in children
2. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the children's cancer group
3. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: Results of the United Kingdom medical research council's 10th AML trial. MRC childhood leukaemia working party
4. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia group B
5. Dose intensification in acute myeloid leukaemia: Greater effectiveness at lower cost. Principal report of the medical research council's AML9 study. MRC leukaemia in adults working party
6. Etoposide in acute nonlymphocytic leukemia. Australian leukemia study group
7. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest oncology group study
8. Pharmacokinetics of teniposide (VM26) and etoposide (VP16-213) in children with cancer
9. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia
10. Diagnosis of childhood acute myeloid leukemia
11. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British cooperative group
12. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia
13. High-performance liquid chromatographic assay for cytosine arabinoside, uracil arabinoside and some related nucleosides
14. High-performance liquid chromatographic analysis of the semisynthetic epipodophyllotoxins teniposide and etoposide using electrochemical detection
15. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic cells after intravenous and subcutaneous administration of 1-beta-D-arabinofuranosylcytosine
16. Nonparametic estimation from incomplete observations
17. Cellular pharmacology and optimal therapeutic concentrations of 1-beta-D-arabinofuranosyl-cytosine 5'-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-beta-D-arabinofuranosylcytosine
18. Pharmacologically directed design of leukemia therapy
19. Metabolism of ara-C by blast cells from patients with ANLL
20. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients
21. High-dose pilot studies in extensive-stage small-cell lung cancer
22. A Randomized study of high-dose cytarabine in induction in acute myeloid leukemia
23. Synchronization of the mitotic cycle in acute leukaemia
24. Rationale for the use of alternating non-cross-resistant chemotherapy
25. Early intensification of chemotherapy for childhood acute nonlymphoblastic leukemia: Improved remission induction with a five-drug regimen including etoposide
26. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM study group
27. Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. A pediatric oncology group pilot study
28. Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion
29. Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the childhood Acute myelogenous leukemia study BFM-87
30. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric oncology group
31. Complications of allogeneic bone marrow transplantation
32. High incidence of obesity in young adults after treatment of acute lymphoblastic leukemia in childhood
33. Definition of a standard-risk group in children with AML